Business · 01/07/2019Updated: 10/17/2026 · 1 min read
FDA Announces Final Guidance for Developing Drugs for Epidermolysis Bullosa
Summary
The FDA has released a final guidance to help pharmaceutical companies develop effective treatments for the skin manifestations of epidermolysis bullosa, a rare genetic disorder.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →